Research and Markets: Otsuka Pharmaceutical & Lundbeck's Co-Produced Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023


Research and Markets ( has announced the addition of the "Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.

Otsuka Pharmaceutical initially developed Brexpiprazole but in 2011, the pharmaceutical company entered an agreement with Lundbeck for the co-development and co-commercialization of this product. The product is in Phase III development as an adjunctive therapy for MDD in the US and Europe, and is also being developed for the treatment of schizophrenia, anxiety disorders, dementia, post-traumatic stress disorder (PTSD), sleep disorders, and ADHD.


  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Brexpiprazole including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Brexpiprazole for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

  • Etiology
  • Pathophysiology
  • Classification
  • Symptoms and Subtypes of Major Depressive Disorder
  • Prognosis
  • Quality of Life

4 Disease Management

  • Diagnosis
  • Treatment Guidelines and Leading Prescribed Drugs
  • Clinical Practice

5 Competitive Assessment

6 Unmet Needs and Opportunities

  • More Effective Pharmacotherapies
  • More Favorable Side Effect Profiles
  • Rapid Onset of Antidepressant Effects
  • Personalized Treatment Approach

7 Pipeline Assessment

8 Brexpiprazole (OPC-34712)

  • Efficacy
  • Safety
  • Dosing and Formulation
  • Potential Clinical and Commercial Positioning
  • SWOT Analysis
  • Forecast

9 Appendix

For more information visit


Rate this press release
3 stars


Add to favourites icon Add to favourites